FlandersBio on Twitter

Follow us on Twitter

Archive for November 2011 - News

Archive for November 2011 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Umbilical cord blood stem cells prime source for transplants and future regenerative medicine


The 5th ITERA Life-Sciences Consortium Symposium took place in Maastricht, the Netherlands, and showcased the progress of stem cell research and promising therapeutic applications. Thanks to solid scientific data, researchers confirmed that umbilical cord blood stem cells are one of the prime sources to be used in current stem cell transplants, ongoing research and future regenerative medicine. read more

ThromboGenics Appoints Thomas Clay as New Board Member


ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that Thomas Clay has been appointed as a non-executive director with immediate effect. read more

Mabcure receives $500,000 licensing fee as well as 12.5% ongoing royalty for its prostate cancer diagnostic technology


MabCure, Inc. (OTCBB: MBCI), a leading developer of antibody-based diagnostics and treatments for ovarian and prostate cancer, today announced that it has signed a license agreement with Biotech Investment Corp. (“Biotech”), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15% of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5% on revenues. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top